To date, several studies show that the ERβ expression is decreased in breast, as well as colon and ovarian cancer (Campbell‐Thompson et al., 2001; Iwao et al., 2000), suggesting that ERβ could function as an inhibitor of tumor initiation in these cancers. Here, ESR2 is linked to ovarian cancer.